TOKEN2049
TOKEN2049 , Asia’s premier crypto conference, has announced a new batch of title sponsors and speakers for its upcoming Singapore edition which will be running from 28 to 29 September. This year marks the conference’s Singapore debut, making for a thrilling week of activities as some of the world’s most pioneering projects gather at what’s set to be the crypto industry’s first major in-person event in Asia ahead of the Formula 1 Singapore Grand Prix 2022 race weekend.
In recognition of growing excitement around the event, TOKEN2049 Singapore’s roster of sponsors grew to 200 firms within the last three weeks. New additions to its line-up of title sponsors include next-generation crypto spot and derivatives trading exchange OKX ; leading hardware wallet manufacturer Ledger ; one of the world’s largest crypto exchanges Kucoin ; Hong Kong-based digital asset exchange AAX ; the world’s largest cryptocurrency derivatives copy trade platform Bitget ; and homegrown Singaporean crypto exchange Coinhako, which secured its major payment institution license earlier this year.
A notable addition to this year's Title Sponsor lineup is a leading South Korean game company WEMADE , best known as the creator of leading MMORPG series Legend of Mir which sees over 120 million players worldwide. WEMADE has been servicing blockchain games since 2020, and currently 14 titles are onboarded on its platform WEMIX , including MIR4, the number 1 play-to-earn MMORPG.
A WEMADE spokesperson said: “With the industry growing at unprecedented levels and the amount of innovation it’s channeling globally, TOKEN2049 and the important conversations that it will catalyse couldn’t have come at a better time.”
As the flagship event of Asia Crypto Week , the conference is expected to draw 3,000 attendees from across the world. This year’s impressive line-up includes Stani Kulechov, Founder and CEO of AAVE, the leading open-source and non-custodial liquidity protocol; Haseeb Kureshi, Managing Partner of Dragonfly Capital; and Eli Ben-Sasson, Co-Founder and President of Starkware and co-inventor of zkSTARK, the privacy-preserving cryptographic proof.
Panels and keynotes at the event are set to address a broad agenda — from the evolving regulatory landscape and institutional investment trends to the rise of the metaverse, Web3, and what this will ultimately mean for the industry as mainstream awareness intensifies.
The Singapore event is set to be the largest in TOKEN2049’s history amid the token economy’s huge potential to transform industries and communities around the world. As a testament to growing interest among broader mainstream audiences, McLaren Racing Formula One driver Daniel Ricciardo, the new brand ambassador for world-leading crypto trading app and web3 platform OKX, will also be speaking at the conference ahead of Sunday’s Singapore Grand Prix 2022 race, sharing his views on digital assets and the evolving nature of fan engagement.
Additional speakers at this year’s conference include Justin Sun, Founder of Tron, the open-source, Proof-of-Stake blockchain platform and Sandeep Nailwal, Co-Founder of Polygon, the decentralised Ethereum scaling platform.
Commenting on the 200-sponsor milestone, Raphael Strauch, Founder of TOKEN2049 said: “The numbers don’t lie, and this overwhelming interest and energy only bode well for the industry. I’m thrilled to see the conversations and solutions that will emerge from Singapore this September.”
As part of Asia Crypto Week, attendees can expect to attend a full line-up of side events, including Pantera Blockchain Summit Asia, Milken Institute Asia Summit, and Algorand AVM Singapore, with many more to be announced in the coming weeks.
For more information and continued updates on TOKEN2049 Singapore, please visit: https://www.asia.token2049.com/
About TOKEN2049:
TOKEN2049 is a premier Web3 event, organised annually in Singapore and London, where decision-makers in the global crypto ecosystem connect to exchange ideas, network, and shape the industry. TOKEN2049 is a global meeting place for entrepreneurs, institutions, industry insiders, investors, and those with a strong interest in the crypto and blockchain industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005567/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom